Literature DB >> 16684317

Oncologic and aesthetic results following breast-conserving therapy with 0.5 cm margins in 100 consecutive patients.

Gregory G Fedorcik1, Robyn Sachs, Michael A Goldfarb.   

Abstract

The purpose of this study was to evaluate the oncologic and aesthetic results of patients undergoing breast-conserving therapy with 0.5 cm surgical margins and determine the factors that influence the need for reconstruction. One hundred consecutive patients who underwent breast-conserving surgery with 0.5 cm surgical margins followed by radiotherapy for invasive cancer and ductal carcinoma in situ (DCIS) were followed prospectively and evaluated for recurrence and aesthetic result. Thirteen patients underwent reexcision to achieve a 0.5 cm margin. Factors including breast size, location of the tumor, specimen size and volume, tumor size and volume, and TNM stage, if axillary dissection or reexcision were required, were included in the analysis. Aesthetic evaluation consisted of both patient rating and an independent observer rating on a 10-point scale that assessed volume, shape, symmetry, areola/nipple, and scar. Of the 100 patients that underwent breast-conserving therapy, the overall aesthetic results revealed that 8% of the patients scored themselves seven or less, another 8% were scored seven or less by the independent observer, and another 7% were scored seven or less by both the patient and the observer. Of these patients, only one proceeded to have a reconstructive procedure. Analysis of variance revealed a significant correlation between tumor size (cm(2)) and an aesthetic score of seven or less (p = 0.023), and specimen volume (cm(3)) and an aesthetic score of seven or less (p = 0.039). Chi-squared analysis revealed a significant difference (chi(2) = 4.39, p < 0.5) in the aesthetic result in patients with stage IIA disease. Other independent factors such as age, breast size, location of the tumor, axillary dissection, and reexcision did not influence the overall aesthetic result. A Pearson correlation of patient and independent observer ratings showed a positive correlation (r = 0.4; 95% confidence interval [CI] 0.19-0.57) between the two groups. There were zero local recurrences of breast cancer during the study period. Our results demonstrate that following breast-conserving therapy with a minimum of 0.5 cm resection margins, it is possible to achieve excellent oncologic and aesthetic results. Patients with large tumors that require a large volume of resection or with stage IIA disease should be considered for reconstructive evaluation.

Entities:  

Mesh:

Year:  2006        PMID: 16684317     DOI: 10.1111/j.1075-122X.2006.00243.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  5 in total

Review 1.  Recent developments in breast-conserving surgery for breast cancer patients.

Authors:  F Fitzal; O Riedl; R Jakesz
Journal:  Langenbecks Arch Surg       Date:  2008-09-10       Impact factor: 3.445

2.  Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.

Authors:  Robert E Neal; Ravi Singh; Heather C Hatcher; Nancy D Kock; Suzy V Torti; Rafael V Davalos
Journal:  Breast Cancer Res Treat       Date:  2010-02-27       Impact factor: 4.872

3.  Health-related quality of life, surgical and aesthetic outcomes following microvascular free flap reconstructions: an 8-year institutional review.

Authors:  R T Dolan; J S Butler; S M Murphy; K J Cronin
Journal:  Ann R Coll Surg Engl       Date:  2012-01       Impact factor: 1.891

4.  Determinants for patient satisfaction regarding aesthetic outcome and skin sensitivity after breast-conserving surgery.

Authors:  Cecilia Dahlbäck; Jonas Manjer; Martin Rehn; Anita Ringberg
Journal:  World J Surg Oncol       Date:  2016-12-07       Impact factor: 2.754

5.  Standardized and reproducible methodology for the comprehensive and systematic assessment of surgical resection margins during breast-conserving surgery for invasive breast cancer.

Authors:  Stephen P Povoski; Rafael E Jimenez; Wenle P Wang; Ronald X Xu
Journal:  BMC Cancer       Date:  2009-07-27       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.